MX2014004678A - Nuevas formas solidas de 1,1-dioxo-4-tiomorfolinil)-[6-[[3(4-fluor ofenil)-5-metil-4-isoxazolil]metoxi]-3-piridinil]-metanona. - Google Patents

Nuevas formas solidas de 1,1-dioxo-4-tiomorfolinil)-[6-[[3(4-fluor ofenil)-5-metil-4-isoxazolil]metoxi]-3-piridinil]-metanona.

Info

Publication number
MX2014004678A
MX2014004678A MX2014004678A MX2014004678A MX2014004678A MX 2014004678 A MX2014004678 A MX 2014004678A MX 2014004678 A MX2014004678 A MX 2014004678A MX 2014004678 A MX2014004678 A MX 2014004678A MX 2014004678 A MX2014004678 A MX 2014004678A
Authority
MX
Mexico
Prior art keywords
solid forms
methanone
thiomorpholinyl
dioxo
isoxazolyl
Prior art date
Application number
MX2014004678A
Other languages
English (en)
Other versions
MX341492B (es
Inventor
Urs Schwitter
Pascal Dott
Andrew Thomas
Olaf Grassmann
Michael Kammerer
Joachim Manns
Nicole Wyttenbach
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2014004678A publication Critical patent/MX2014004678A/es
Publication of MX341492B publication Critical patent/MX341492B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a nuevas formas sólidas del compuesto de la fórmula (I) (ver Fórmula) así como a solvatos, complejos de inclusión con otros compuestos idóneos, a procesos de obtención, a composiciones farmacéuticas que contienen estas formas sólidas y a su utilización como medicamentos.
MX2014004678A 2011-10-20 2012-10-17 Nuevas formas solidas de 1,1-dioxo-4-tiomorfolinil)-[6-[[3(4-fluor ofenil)-5-metil-4-isoxazolil]metoxi]-3-piridinil]-metanona. MX341492B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11185993 2011-10-20
PCT/EP2012/070522 WO2013057124A1 (en) 2011-10-20 2012-10-17 Solid forms of 1,l-dioxo-4-thiomorpholinyl)-[6-[[3(4-fluorophenyl)-5-methyl-4-isoxazolyl]methoxy]-3-pyridinyl]-methanone

Publications (2)

Publication Number Publication Date
MX2014004678A true MX2014004678A (es) 2014-05-28
MX341492B MX341492B (es) 2016-08-23

Family

ID=47019027

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014004678A MX341492B (es) 2011-10-20 2012-10-17 Nuevas formas solidas de 1,1-dioxo-4-tiomorfolinil)-[6-[[3(4-fluor ofenil)-5-metil-4-isoxazolil]metoxi]-3-piridinil]-metanona.

Country Status (20)

Country Link
US (2) US8785435B2 (es)
EP (1) EP2768821B1 (es)
JP (1) JP5918856B2 (es)
KR (1) KR20140079503A (es)
CN (1) CN103889971B (es)
AR (1) AR088359A1 (es)
AU (1) AU2012318294B2 (es)
BR (1) BR112014009288A8 (es)
CA (1) CA2850441A1 (es)
DK (1) DK2768821T3 (es)
ES (1) ES2606547T3 (es)
HK (1) HK1193611A1 (es)
HU (1) HUE030298T2 (es)
IL (1) IL231532A0 (es)
MX (1) MX341492B (es)
PL (1) PL2768821T3 (es)
RU (1) RU2618524C2 (es)
SG (1) SG11201401591WA (es)
SI (1) SI2768821T1 (es)
WO (1) WO2013057124A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
EA202090521A1 (ru) 2017-08-28 2020-06-10 Юниверсити Оф Мэриленд, Балтимор Новые модуляторы рецептора гамма-аминомасляной кислоты типа a против расстройств настроения
CN112424196A (zh) 2018-06-13 2021-02-26 豪夫迈·罗氏有限公司 作为GABAAα5 PAM的新型异噁唑基醚衍生物

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE352505C (de) 1918-03-01 1922-04-27 Metallbank Verfahren zur Verarbeitung von Salmiakschlacken
DE3525205A1 (de) 1984-09-11 1986-03-20 Hoechst Ag, 6230 Frankfurt Pflanzenschuetzende mittel auf basis von 1,2,4-triazolderivaten sowie neue derivate des 1,2,4-triazols
GB9808663D0 (en) 1998-04-23 1998-06-24 Merck Sharp & Dohme Therapeutic agents
EP1102755B1 (en) 1998-08-07 2006-01-04 Chiron Corporation Substituted isoxazole derivatives as estrogen receptor modulators
US6297256B1 (en) 1999-06-15 2001-10-02 Neurogen Corporation Aryl and heteroaryl substituted pyridino derivatives GABA brain receptor ligands
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
IT1314191B1 (it) 1999-10-18 2002-12-06 Recordati Chem Pharm Derivati isossazolcarbossamidici
US6511987B1 (en) 1999-11-12 2003-01-28 Neurogen Corporation Bicyclic and tricyclic heteroaromatic compounds
PA8535601A1 (es) 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
GB0108475D0 (en) 2001-04-04 2001-05-23 Merck Sharp & Dohme New compounds
WO2003004027A1 (en) 2001-07-05 2003-01-16 Synaptic Pharmaceutical Corporation Substituted anilinic piperidines as mch selective antagonists
DE60131967D1 (de) 2001-08-13 2008-01-31 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
DE60225174T2 (de) 2001-11-20 2009-02-12 Eli Lilly And Co., Indianapolis Beta-3 adrenergische agonisten
GB0128160D0 (en) 2001-11-23 2002-01-16 Merck Sharp & Dohme Novel compounds
GB0128499D0 (en) 2001-11-28 2002-01-23 Merck Sharp & Dohme Therapeutic agents
WO2004048349A1 (en) 2002-11-22 2004-06-10 Smithkline Beecham Corporation Farnesoid x receptor agonists
WO2005118568A1 (en) 2004-06-01 2005-12-15 F. Hoffmann-La Roche Ag Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as mglu5 receptor antagonists
GB0318447D0 (en) 2003-08-05 2003-09-10 Merck Sharp & Dohme Therapeutic agents
AU2005245411B2 (en) 2004-05-14 2009-04-23 Irm Llc Compounds and compositions as PPAR modulators
WO2005123672A2 (en) 2004-06-14 2005-12-29 Takeda San Diego, Inc. Kinase inhibitors
JP4620123B2 (ja) 2004-10-01 2011-01-26 エフ．ホフマン−ラ ロシュ アーゲー ヘキサフルオロイソプロパノール置換エーテル誘導体
US7351724B2 (en) 2004-10-15 2008-04-01 The Scripps Research Institute Oxadiazole ketone inhibitors of fatty acid amide hydrolase
US20070060589A1 (en) 2004-12-21 2007-03-15 Purandare Ashok V Inhibitors of protein arginine methyl transferases
WO2006095822A1 (ja) 2005-03-11 2006-09-14 Ono Pharmaceutical Co., Ltd. スルホンアミド化合物およびその医薬
US7700620B2 (en) 2005-06-27 2010-04-20 Bristol-Myers Squibb Company C-linked cyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
ATE532668T1 (de) 2005-07-20 2011-11-15 Prospective Concepts Ag Pneumatische kissenstrukturen
DE602006003777D1 (de) 2005-09-19 2009-01-02 Hoffmann La Roche Isoxazolderivate als inverse gaba a alpha5 agonisten
BRPI0617306A2 (pt) 2005-10-11 2011-07-19 Hoffmann La Roche derivados de isoxazol
WO2007052843A1 (ja) 2005-11-04 2007-05-10 Takeda Pharmaceutical Company Limited 複素環アミド化合物およびその用途
EP1968967B1 (en) * 2005-11-30 2011-04-27 F. Hoffmann-La Roche AG 1,1-dioxo-thiomorpholinyl indolyl methanone derivatives for use as h3 modulators
US7705028B2 (en) 2005-12-19 2010-04-27 Glaxosmithkline Llc Farnesoid X receptor agonists
WO2007071476A1 (en) * 2005-12-20 2007-06-28 International Business Machines Corporation Method, system and computer program for distributing software products based on an e-mail service
AU2007212126B2 (en) 2006-02-03 2012-07-19 Eli Lilly And Company Compounds and methods for modulating FX-receptors
JP2007230909A (ja) 2006-03-01 2007-09-13 Univ Of Tokyo 置換イソキサゾール誘導体
MX2008014796A (es) 2006-05-31 2008-12-02 Hoffmann La Roche Derivados de aril-4-etinil-isoxazol.
EP1894928A1 (en) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
EP1894924A1 (en) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
EP2142551B1 (en) 2007-04-17 2015-10-14 Bristol-Myers Squibb Company Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type i inhibitors
JP5301556B2 (ja) 2007-12-04 2013-09-25 エフ．ホフマン−ラ ロシュ アーゲー イソオキサゾロ−ピラジン誘導体
KR20120102117A (ko) 2007-12-04 2012-09-17 에프. 호프만-라 로슈 아게 아이속사졸로-피리딘 유도체

Also Published As

Publication number Publication date
SI2768821T1 (sl) 2017-01-31
AU2012318294B2 (en) 2015-10-01
BR112014009288A8 (pt) 2020-04-22
SG11201401591WA (en) 2014-05-29
HUE030298T2 (en) 2017-04-28
EP2768821B1 (en) 2016-11-16
RU2618524C2 (ru) 2017-05-04
US8975397B2 (en) 2015-03-10
PL2768821T3 (pl) 2017-05-31
NZ622215A (en) 2016-06-24
AU2012318294A1 (en) 2013-05-09
US8785435B2 (en) 2014-07-22
RU2014118968A (ru) 2015-11-27
CA2850441A1 (en) 2013-04-25
KR20140079503A (ko) 2014-06-26
JP2014530832A (ja) 2014-11-20
MX341492B (es) 2016-08-23
CN103889971A (zh) 2014-06-25
DK2768821T3 (en) 2017-01-23
IL231532A0 (en) 2014-04-30
AR088359A1 (es) 2014-05-28
US20130172329A1 (en) 2013-07-04
ES2606547T3 (es) 2017-03-24
HK1193611A1 (zh) 2014-09-26
EP2768821A1 (en) 2014-08-27
WO2013057124A1 (en) 2013-04-25
CN103889971B (zh) 2016-08-31
BR112014009288A2 (pt) 2017-06-13
US20140329806A1 (en) 2014-11-06
JP5918856B2 (ja) 2016-05-18

Similar Documents

Publication Publication Date Title
GEP20217235B (en) Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
MX2011008864A (es) Tetrahidroazolopirazinas sulfoniladas y su uso como productos medicinales.
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
PH12017500755A1 (en) 2 substituted cephem compounds
EA201001683A1 (ru) Производные фенил- или пиридинилзамещенных индазолов
MD4664C9 (ro) Lactame aril şi heteroaril condensate
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
MX2011011661A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
PH12014501179B1 (en) New bicyclic dihydroisoquinoline-1-one derivatives
GEP201606555B (en) Compounds and compositions for modulating egfr activity
PH12015501609A1 (en) Phenicol antibacterials
MD20140136A2 (ro) Inhibitori ai virusului hepatic C
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
IN2014CN04530A (es)
MY186599A (en) Substituted pyridopyrazines as novel syk inhibitors
EA201200471A1 (ru) Простые эфирные производные бициклических гетероарилов
MX2012013274A (es) Novedosos derivados de la pirimidina.
MY169267A (en) New aryl-quinoline derivatives
GEP201606598B (en) Heteroaromatic compounds as dopamine d1 ligands
MX2012006909A (es) LIGANDOS DEL RECEPTOR NICOTINICO NEURONAL A4ß2 DE ACETILCOLINA.
TW200738627A (en) Trialkylsilyl-indoles
TN2016000003A1 (en) New isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them
MY152018A (en) Indole derivatives as anticancer agents
MX341492B (es) Nuevas formas solidas de 1,1-dioxo-4-tiomorfolinil)-[6-[[3(4-fluor ofenil)-5-metil-4-isoxazolil]metoxi]-3-piridinil]-metanona.
IN2015DN02109A (es)

Legal Events

Date Code Title Description
FG Grant or registration